Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06717919 · ClinicalTrials.gov registry record · Phase 4
HOPE Against Cancer Recurrence in HCC
A Phase 4 study of HCC and Liver Transplantation, sponsored by Philipp Dutkowski.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06717919: Recruiting Phase 4 study of HCC and Liver Transplantation, sponsored by Philipp Dutkowski.
NCT06717919 is a Phase 4 study of HCC and Liver Transplantation that is actively recruiting participants, run by Philipp Dutkowski. The registered enrollment target is 220 participants, above the 185-participant average among 13 other HCC trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06717919, a Phase 4 study of HCC and Liver Transplantation, is actively recruiting participants, sponsored by Philipp Dutkowski.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this depends on the quality of the liver received. Machine liver perfusion, for example, hypothermic oxygenated liver perfusion (HOPE), which means that the organ is perfused with an oxygen-rich fluid in a cold environment before transplantation, is a novel method to improve the quality of livers before implantation. The standard of care is cold storage without perfusion. The objective of this study is to compare the survival after tumor recurrence of patients after liver transplantation for HCC between perfused and not perfused livers. This study's hypothesis is that survival without tumor recurrence is improved when the liver is perfused before implantation. The study involves transplant centers worldwide, and adults with HCC waiting for liver transplantation are included. 220 Patients will be recruited within 12 months and then observed for at least 2 years after transplantation. To provide the most valid results, the patients will be randomly allocated to either the organ perfusion group or a control group with standard-of-care cold storage of the organ.
Primary Outcome
Post transplant HCC recurrence free survival, i.e. the time interval a patient is alive without HCC recurrence after transplantation, i.e., until either HCC recurrence is observed, or the patient dies from any cause.
Conditions Studied
Interventions
- PROCEDURE Hypothermic oxygenated perfusion
- PROCEDURE Conventional cold storage
Study Locations (20)
Other
- Medical University of Innsbruck - Innsbruck
- Medical University of Vienna - Vienna
- University Hospitals Leuven - Leuven
- Institut de Recherche Expérimentale et Clinique (IREC) UCLouvain (Brussels) - Woluwe-Saint-Lambert
- Institute for Clinical and Experimental Medicine (IKEM) (Prague) - Prague
- Copenhagen University Hospital - Copenhagen
- Hôpital de la Croix-Rousse (Lyon) - Lyon
- Universitätsklinikum Essen - Essen
- University Medical Centre Hamburg-Eppendorf - Hamburg-Eppendorf
- Hannover Medical School - Hanover
- University of Heidelberg - Heidelberg
- University of Mainz - Mainz
- University of Munich Grosshadern - München
- Milano Institutio Nazionale dei Tumori (Milan) - Milan
- ASST Grande Ospedale Metropolitano Niguarda (Milan) - Milan
- Padova University Hospital - Padua
- Gemelli University Hospital - Rome
- University of Udine - Udine
New York
- Rutgers New Jersey Medical School (New York) - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 4 |
What NCT06717919 shows while recruiting
NCT06717919 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 185-participant average among 13 other HCC trials with a reported enrollment target (19% higher).
The record links to 3 conditions, with HCC appearing as the primary indexed condition, and to 2 interventions - of which Hypothermic oxygenated perfusion is the first listed.
NCT06717919 names 20 study sites across 3 states, led by Other, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT06717919 about?
NCT06717919 is a clinical study titled "HOPE Against Cancer Recurrence in HCC". Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this...
What is the current status of trial NCT06717919?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2025-08-01. Estimated completion is 2028-01-31.
What conditions does trial NCT06717919 study?
This clinical trial studies the following conditions: HCC, Liver Transplantation, Oncological Outcomes.
What interventions are being tested in trial NCT06717919?
The interventions under investigation include: Hypothermic oxygenated perfusion (PROCEDURE), Conventional cold storage (PROCEDURE).
Who is sponsoring clinical trial NCT06717919?
This trial is sponsored by Philipp Dutkowski, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06717919 being conducted?
This trial has 20 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06717919's enrollment target sits among peer trials
220 3rd of 13 higher than 11 of 13 other HCC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HCC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC
RECRUITING · Phase 1
-
Effect of the HCC Liver-Link Intervention
RECRUITING · NA
-
Optimizing Y90 Therapy for Radiation Lobectomy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI